Janssen Can't Use Tenn. Law To Nix $70M Risperdal Verdict

Law360 (November 26, 2019, 8:14 PM EST) -- A Johnson & Johnson unit can't cite a Tennessee law to duck a Philadelphia jury's $70 million compensatory damages award to a male patient whose use of the antipsychotic drug Risperdal since he was 4½ led him to develop breasts, the Superior Court of Pennsylvania ruled Tuesday.

The three-judge panel affirmed the September 2016 verdict in favor of the plaintiffs, identified only as 20-year-old Tennessee resident A.Y. and his mother, ruling that the trial court was right to reject Janssen Pharmaceuticals' argument that it was impossible to comply with both Tennessee law and federal law for labeling Risperdal and stating its...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS